Urothelial Carcinoma
349
86
127
107
Key Insights
Highlights
Success Rate
69% trial completion
Published Results
56 trials with published results (16%)
Research Maturity
107 completed trials (31% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 59/100
14.0%
49 terminated out of 349 trials
68.6%
-17.9% vs benchmark
5%
18 trials in Phase 3/4
52%
56 of 107 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 107 completed trials
Clinical Trials (349)
A Study of GEN1106 in Participants With Solid Tumors
Bladder Cancer Screening Trial
Phase II Study of Trastuzumab Rezetecan or in Combination With Adebrelimab in HER2-Expressing Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC)
Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma at High-Risk Recurrence
A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer
A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)
Efficacy and Utility of Cxbladder Tests in Hematuria Patients
Detection and Risk Stratification in Veterans Presenting With Microscopic Hematuria
Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
Study of DCC-2812 in Participants With Advanced Genitourinary Cancers
Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2
A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Urothelial Carcinoma(PANKU-Bladder01)
Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer
A Phase 1 Clinical Trial of AUR106 in Patients With Relapsed Advanced Malignancies
Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC
A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor Cancer
Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the Bladder
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors
An Expanded Access Program of Cretostimogene Grenadenorepvec for Treatment of NMIBC for Patients Unresponsive to BCG